<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6E67417F-B80E-4C95-BF96-FB92B017EF03"><gtr:id>6E67417F-B80E-4C95-BF96-FB92B017EF03</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Gardiner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2C9BD9EC-D907-459F-B3C5-90B22288D628"><gtr:id>2C9BD9EC-D907-459F-B3C5-90B22288D628</gtr:id><gtr:firstName>Gordon</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Jayson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601746"><gtr:id>E22ABD5D-754A-40C1-969A-C2E5582CC1D3</gtr:id><gtr:title>The structure and function of antiangiogenic oligosaccharides</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601746</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Angiogenesis, the formation of new blood vessels, has been validated in several randomised trials as a target for anti-cancer treatment. Drugs that inhibit Vascular Endothelial Growth Factor (VEGF) augment the benefits of cytotoxic chemotherapy and improve the median survival of patients with solid tumours. However, the long term survival from advanced cancer has improved to a lesser extent and we need to increase the benefit associated with this new class of drugs by inhibiting additional angiogenic cytokines.
Several angiogenic growth factors are dependent on cell surface heparan sulfate (HS) for their
biological activity. We have shown that heparin octasaccharides inhibit angiogenesis in vitro and in vivo and this is mediated through the competitive inhibition of heparan sulfate-mediated activation of FGF2. Our synthesis programme has developed the first scalable and inexpensive method to generate large amounts of the key iduronate unit and application to heparin octasaccharides has enabled larger scale provision of these saccharides which have anti-angiogenic activity. We therefore propose to generate, characterise and investigate several families of heparan sulfate based saccharides with respect to their ability to inhibit the angiogenic cytokines FGF2 and VEGF165,189,202 (the HS-dependent isoforms of VEGF):
HS octasaccharides: We will generate a range of site-specifically sulfated octasaccharides to
establish the most critical sulfate groups on the saccharide backbone that determine FGF2 and
VEGF activity.
Anionically substituted octasaccharides will be made that incorporate different anionic
substitutions at sites identified as being critical through the HS octasaccharides set of molecules
(above).
Dimerised octasaccharides: We will evaluate the impact of dimerised oligosaccharides using
parallel or anti-parallel linkers and also investigate the impact of increasing the linker chain length on FGF2 and VEGF activity in vitro and in vivo. This strategy will provide a platform technology to address the synthesis of an array of spacer-variable heparin systems to probe for multi-target effects.
This innovative approach will generate several types of completely novel molecules that will
establish our team as the UK glycotherapeutics unit, enhanced by the key synergy between design and synthesis of specific novel heparin-based targets allied to a leading international facility in heparin/cancer biology; a programme that will lead directly to further testing in the oncology clinic.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-14</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-12-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>300000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry Manchester</gtr:department><gtr:description>Development of Oligosaccharides as Anti-Angiogenic Agents</gtr:description><gtr:id>56AEDB9E-EBB5-4397-9C5E-ADEE51212F3A</gtr:id><gtr:impact>We have elucidated and patented the first inexpensive and scalable synthesis of L-iduronate, a saccharide that is essential for heparan sulfate structure. We have then progressed the chemistry so that we can generate using scalable chemistry, oligosaccharide species containing 12 residues bearing spatially defined sulfate residues. This resulted in the second patent published in July 2009. The first patent has been published this year in Org Lett (Pubmed 19764712). The patents are: Production of L-Iduronate containing polysaccharides, Int. publication: WO 2006/129075 A1: 2006-12-07 Jayson G, Gardiner J, Hansen S Synthesis route for multioligomeric heparan sulfate molecules, PCT Application : PCT/ GB2009/ 000300, 2009-02-04 Jayson G, Gardiner J, Hansen S</gtr:impact><gtr:outcomeId>674E0698C7A-1</gtr:outcomeId><gtr:partnerContribution>We are translating the field of heparan sulfate proteoglycans towards human ovarian cancer angiogenesis. The oligosaccharide programme forms one work stream of the overall programme.</gtr:partnerContribution><gtr:piContribution>I have been the PI on all grants emerging from the collaboration between Cancer Studies and Organic Chemistry. The ideas and drive emerged from my post-doctoral work in angiogenesis and the critical contribution of heparan sulfate to this phenotype. Dr. Gardiner's group developed the chemistry and synthesised the oligosaccharides and we subsequently evaluated the compounds in vitro.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Research UK London Research Institute (LRI)</gtr:department><gtr:description>In vivo evaluation of oligosaccharides as anti-angiogenic agents</gtr:description><gtr:id>790816AF-6DEC-46C4-85F5-340CB21938A9</gtr:id><gtr:impact>The collaboration has only been established in November 2009. It is too early for an output</gtr:impact><gtr:outcomeId>97DA8CCFB91-1</gtr:outcomeId><gtr:partnerContribution>Egle Avizienyte, Graham Rushton and Claire Cole- Contributed towards the in vivo experiments.</gtr:partnerContribution><gtr:piContribution>We developed and evaluated the oligosaccharides using the chemistry described above. We have now established a collaboration with Dr. Holger Gerhardt (Inst. Cancer Research, London) who has some novel models of angiogenesis allowing us to evaluate the molecules in vivo.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Lecturing at Schools</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E863FB15-F012-44B0-9BEA-63C8478BF6E8</gtr:id><gtr:impact>I lecture regularly at schools and teach them about cancer. Included in this is some limited information about the sort of research that I am carrying out.

None known.</gtr:impact><gtr:outcomeId>374F7D9CEC4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Fund raising for Christie Hospital</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>56712EB8-12B7-48CD-B7C8-C4FE71C4DBC7</gtr:id><gtr:impact>Lecturing on the research that I carry out to potential funders for the Hospital

Left with the charitable funds committee at the Hospital</gtr:impact><gtr:outcomeId>658B48A3E50</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture to public on ovarian cancer</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>93DED8D6-B4DC-4E6D-B051-E909BF82FE51</gtr:id><gtr:impact>I lecture regularly to patients and relatives groups on ovarian cancer. In addition to a general background on the disease I told them about this research programme

Not known</gtr:impact><gtr:outcomeId>0DE071D9063</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>980000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DPFS MRC scheme</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>25131763-82AB-493C-84E9-0BD14054DF29</gtr:id><gtr:outcomeId>SjGfprEbWQy0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>29022</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Discovery Committee (Development of Oligosaccharides as Anti-angiogenic agents)</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>D74C5259-7B48-4896-996E-DF423950051E</gtr:id><gtr:outcomeId>1E77283525B0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This patent describes the extended synthesis from mono- to oligosaccharides using scalable chemistry</gtr:description><gtr:grantRef>G0601746</gtr:grantRef><gtr:id>8CA18E21-527A-4518-9B13-E7B4430B0F55</gtr:id><gtr:impact>This grant also forms an essential part of our programme where we are generating and evaluating oligosaccharides as anti-angiogenic agents.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>A3860F7D0B3</gtr:outcomeId><gtr:patentId>EP2245074</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Synthesis route for multioligomeric heparan sulfate molecules</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The patent covers the first inexpensive and scalable synthesis of L-iduronate, a saccharide that forms an essential part of the heparan sulfate backbone</gtr:description><gtr:grantRef>G0601746</gtr:grantRef><gtr:id>E2BEA5D4-35D4-44C9-9AC2-BBF5113B827B</gtr:id><gtr:impact>This patent forms the basis of our oligosaccharide development and evaluation programme</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>20600D40F14</gtr:outcomeId><gtr:patentId>US2009137792</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Production of L-Iduronate containing polysaccharides</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>We are currently completing milestone 1 of the MRC DPFS grant.</gtr:description><gtr:id>48CDC3B0-8ACB-49D9-BFB9-2D02E4163219</gtr:id><gtr:impact>We published structure function relationships for synthetic heparan sulfate oligosaccharides in PLoS ONE this summer.</gtr:impact><gtr:outcomeId>2AAEFF5C38F</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Anti-angiogenic oligosaccharide</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed an assay to define the composition of heparan and chondroitin sulfate in the plasma of patients receiving treatment for ovarian and endmetrial cancer. The assay is based on the fluorescent labelling of depolymerised glycosaminoglycans that are then separated and identified using reverse phase HPLC.</gtr:description><gtr:id>995017AA-9335-43B4-BA1A-D00E52CF0C88</gtr:id><gtr:impact>We have just developed this technology and are starting to evaluate patients' plasma samples now.</gtr:impact><gtr:outcomeId>3E3D77F9082</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Development of methodology to analyse glycosaminoglycans and proteoglycans in patients' plasma samples</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated two series of heparan sulfate oligosaccharides each of which contains molecules containing up to 12 saccharide residues. The molecules have been uniformly sulfated so that they contain either one or two sulfate residues per disaccharide.</gtr:description><gtr:id>C414095D-DE2C-40F4-BAC2-4E27FCA59456</gtr:id><gtr:impact>We have demonstrated clear structure activity relationships based on size and sulfation patterns. Two patents have been published based on this programme. We have applied to the MRC DPFS scheme to take the molecules towards the clinic.</gtr:impact><gtr:outcomeId>6B99B64F618</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Synthesis of series of structurally defined heparan sulfate oligosaccharides</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9AE59786-0AF9-4AD0-8C99-294B27AA4ADC</gtr:id><gtr:title>Imaging angiogenesis of genitourinary tumors.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95114ba6b9e8321e1dafa232fbe4aa7c"><gtr:id>95114ba6b9e8321e1dafa232fbe4aa7c</gtr:id><gtr:otherNames>Zee YK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>jqAq3L5U99M</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>335A7A79-8549-4579-A519-603F6F9B90F4</gtr:id><gtr:title>Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd2e75d490ef51aca47497ceaaa0a939"><gtr:id>cd2e75d490ef51aca47497ceaaa0a939</gtr:id><gtr:otherNames>Rustin GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>VHLyMna6fHu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEB3EA37-EEB3-4836-8306-B068D887372C</gtr:id><gtr:title>A longitudinal investigation of psychological disorders in patients prior and subsequent to a diagnosis of ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical psychology in medical settings</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7973b74c6802ba960c42a788c96446ff"><gtr:id>7973b74c6802ba960c42a788c96446ff</gtr:id><gtr:otherNames>Gon?alves V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1068-9583</gtr:issn><gtr:outcomeId>i9YdFp319yn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF0BE3BC-1E85-4753-9088-BA09AE763A20</gtr:id><gtr:title>Tracer kinetic model-driven registration for dynamic contrast-enhanced MRI time-series data.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dcfa78e54650275267b086a6715f192"><gtr:id>7dcfa78e54650275267b086a6715f192</gtr:id><gtr:otherNames>Buonaccorsi GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>DAC551C4E3B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DA5564A-859D-46CA-A934-172801200332</gtr:id><gtr:title>Oligosaccharides as anti-angiogenic agents.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0115694f3825ebf31244b421484b7bae"><gtr:id>0115694f3825ebf31244b421484b7bae</gtr:id><gtr:otherNames>Cole CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn><gtr:outcomeId>C9DC3959C7E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3072986D-FBD0-4998-8F20-682E81767E9A</gtr:id><gtr:title>Quantitative multiplexed quantum dot immunohistochemistry.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b51a2df7633b371a4d0d68d08e1486b"><gtr:id>4b51a2df7633b371a4d0d68d08e1486b</gtr:id><gtr:otherNames>Sweeney E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>5242F69B0B1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8338387-4678-4CE1-A337-646C10B200CE</gtr:id><gtr:title>Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement.</gtr:title><gtr:parentPublicationTitle>Academic radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dcfa78e54650275267b086a6715f192"><gtr:id>7dcfa78e54650275267b086a6715f192</gtr:id><gtr:otherNames>Buonaccorsi GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1076-6332</gtr:issn><gtr:outcomeId>DDB12F5F533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F78C5310-18FF-479C-A409-CA38376DE822</gtr:id><gtr:title>A longitudinal investigation of psychological morbidity in patients with ovarian cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7973b74c6802ba960c42a788c96446ff"><gtr:id>7973b74c6802ba960c42a788c96446ff</gtr:id><gtr:otherNames>Gon?alves V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>CF0086E46BC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C2D0EB7-413A-4E61-A0EE-DF1A462AB6A3</gtr:id><gtr:title>Synthetic heparan sulfate dodecasaccharides reveal single sulfation site interconverts CXCL8 and CXCL12 chemokine biology.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de2ffbfbd3a541e8a4ed5d196f67c490"><gtr:id>de2ffbfbd3a541e8a4ed5d196f67c490</gtr:id><gtr:otherNames>Jayson GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>5675e9abed789</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>844DEAF6-014D-4DEC-BC1C-844D58F992B3</gtr:id><gtr:title>The development of anti-angiogenic heparan sulfate oligosaccharides.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de2ffbfbd3a541e8a4ed5d196f67c490"><gtr:id>de2ffbfbd3a541e8a4ed5d196f67c490</gtr:id><gtr:otherNames>Jayson GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>546cab7dc59bc1.53685622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>340EBADB-EE3D-4034-8B8E-4DFA7D95BD90</gtr:id><gtr:title>A latent reactive handle for functionalising heparin-like and LMWH deca- and dodecasaccharides.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b108ba399454ec071f629b8aea25ffb"><gtr:id>1b108ba399454ec071f629b8aea25ffb</gtr:id><gtr:otherNames>Miller GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>56cf0cbccb8509.61439723</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D7F1527-1F9A-4FC6-8EA0-0D3CCD12E5BA</gtr:id><gtr:title>Antiangiogenic therapy for ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Current opinion in oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08a5dbaad5acf73619f1083930308d3c"><gtr:id>08a5dbaad5acf73619f1083930308d3c</gtr:id><gtr:otherNames>Rosa DD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1040-8746</gtr:issn><gtr:outcomeId>E87FC1171ED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7279BA31-5BE2-4F94-B4CE-3E24E167D893</gtr:id><gtr:title>Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5ea2465d89ab80d88bb7a209ef1aa86"><gtr:id>a5ea2465d89ab80d88bb7a209ef1aa86</gtr:id><gtr:otherNames>Byrd LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>E698A7BC9D4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9515DDA5-DACE-4E3D-B339-FB6BDD34815F</gtr:id><gtr:title>Synthesis of L-iduronic acid derivatives via [3.2.1] and [2.2.2] L-iduronic lactones from bulk glucose-derived cyanohydrin hydrolysis: a reversible conformationally switched superdisarmed/rearmed lactone route to heparin disaccharides.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45847ebe50cfcf60d4977b6bc361f884"><gtr:id>45847ebe50cfcf60d4977b6bc361f884</gtr:id><gtr:otherNames>Hansen SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>doi_55f9849842a8040e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9671866A-BF61-4F57-BA74-12E4066566C8</gtr:id><gtr:title>Stage- and CA125-related survival in patients with epithelial ovarian cancer treated at a cancer center.</gtr:title><gtr:parentPublicationTitle>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/394d3a1cc32c31e5e75691c852d84dac"><gtr:id>394d3a1cc32c31e5e75691c852d84dac</gtr:id><gtr:otherNames>Board RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1048-891X</gtr:issn><gtr:outcomeId>ED9A8F57DD2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C101A883-21CC-49E6-8BCD-2DC4D01A910C</gtr:id><gtr:title>Scalable synthesis of L-iduronic acid derivatives via stereocontrolled cyanohydrin reaction for synthesis of heparin-related disaccharides.</gtr:title><gtr:parentPublicationTitle>Organic letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45847ebe50cfcf60d4977b6bc361f884"><gtr:id>45847ebe50cfcf60d4977b6bc361f884</gtr:id><gtr:otherNames>Hansen SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1523-7052</gtr:issn><gtr:outcomeId>E6yBNgkejbR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC21D67C-CDED-4B99-8039-7BC13BF4CEE6</gtr:id><gtr:title>Cross-visit tumor sub-segmentation and registration with outlier rejection for dynamic contrast-enhanced MRI time series data.</gtr:title><gtr:parentPublicationTitle>Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dcfa78e54650275267b086a6715f192"><gtr:id>7dcfa78e54650275267b086a6715f192</gtr:id><gtr:otherNames>Buonaccorsi GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>abxwbnzeR2U</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B276017F-606F-46F8-91AD-3AF9F6B6476E</gtr:id><gtr:title>Efficient chemical synthesis of heparin-like octa-, deca- and dodecasaccharides and inhibition of FGF2- and VEGF165-mediated endothelial cell functions</gtr:title><gtr:parentPublicationTitle>Chemical Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/529658a9cdd14ca4e07f174b9c438cce"><gtr:id>529658a9cdd14ca4e07f174b9c438cce</gtr:id><gtr:otherNames>Miller G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_55f9849842b09826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F779E4E-2223-4ADB-8A26-76E2DD67AFF4</gtr:id><gtr:title>Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b2773ce0b8cff611563d31271ea10f4"><gtr:id>7b2773ce0b8cff611563d31271ea10f4</gtr:id><gtr:otherNames>Murukesh N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>iwmRUBox67D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDF50C19-6F94-4BA2-A032-72082BEDBBC2</gtr:id><gtr:title>Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Cancer biology &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22b06ec69d0137bb4a231178d116e464"><gtr:id>22b06ec69d0137bb4a231178d116e464</gtr:id><gtr:otherNames>Cole C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1538-4047</gtr:issn><gtr:outcomeId>GGVebPBK9Jd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41824C41-9CFF-4432-8892-CFCC77841D3D</gtr:id><gtr:title>Weekly paclitaxel in the treatment of recurrent ovarian carcinoma.</gtr:title><gtr:parentPublicationTitle>European journal of gynaecological oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2ea26fcbcd1c02799cd36059c0d8d1a"><gtr:id>c2ea26fcbcd1c02799cd36059c0d8d1a</gtr:id><gtr:otherNames>Byrd L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0392-2936</gtr:issn><gtr:outcomeId>8434CBBD4D0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82F524CA-2334-4D43-B4B4-DC17EAC4AE97</gtr:id><gtr:title>Making the longest sugars: a chemical synthesis of heparin-related [4]
 
 oligosaccharides from 16-mer to 40-mer</gtr:title><gtr:parentPublicationTitle>Chemical Science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b0ee5cdddee4e6c221066d68c87a347"><gtr:id>2b0ee5cdddee4e6c221066d68c87a347</gtr:id><gtr:otherNames>Hansen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>585d366c60c649.88846942</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6063540-2C8D-4914-BBFC-24F56E7E95DB</gtr:id><gtr:title>Synthetic Site-Selectively Mono-6-O-Sulfated Heparan Sulfate Dodecasaccharide Shows Anti-Angiogenic Properties In Vitro and Sensitizes Tumors to Cisplatin In Vivo.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73497dd4df75fa96d6cca04f2ab34165"><gtr:id>73497dd4df75fa96d6cca04f2ab34165</gtr:id><gtr:otherNames>Avizienyte E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d3f0f46d737.69930583</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFD5FAC3-C815-47D4-9CDB-968977CB22DB</gtr:id><gtr:title>Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ff5fe08eee4c64c11545d51606d3218"><gtr:id>2ff5fe08eee4c64c11545d51606d3218</gtr:id><gtr:otherNames>Parker GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>A4F9F3F96DC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CCC0FBA-D4EB-41E0-9062-C3095AE1D30F</gtr:id><gtr:title>First gram-scale synthesis of a heparin-related dodecasaccharide.</gtr:title><gtr:parentPublicationTitle>Organic letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45847ebe50cfcf60d4977b6bc361f884"><gtr:id>45847ebe50cfcf60d4977b6bc361f884</gtr:id><gtr:otherNames>Hansen SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1523-7052</gtr:issn><gtr:outcomeId>546cae0f3c5607.47701898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84F26392-F7B6-4AA0-9FC5-81FC1A49F273</gtr:id><gtr:title>Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fb102f2c31f5f6d2916b8d15afa7ada"><gtr:id>3fb102f2c31f5f6d2916b8d15afa7ada</gtr:id><gtr:otherNames>Ton NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>B943EED9C21</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0B9405C-221F-4314-A675-198F231AC588</gtr:id><gtr:title>The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma.</gtr:title><gtr:parentPublicationTitle>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08a5dbaad5acf73619f1083930308d3c"><gtr:id>08a5dbaad5acf73619f1083930308d3c</gtr:id><gtr:otherNames>Rosa DD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0748-7983</gtr:issn><gtr:outcomeId>DE02DD01107</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58784477-4EF3-4D47-8F07-2B5725964BC3</gtr:id><gtr:title>Organ-specific effects of oxygen and carbogen gas inhalation on tissue longitudinal relaxation times.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>84209E3E5E8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1DA796D-E2BF-4E7C-8635-91D4DF8DA50E</gtr:id><gtr:title>Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>A4BDE535B9E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78D95AD8-BE15-4AFD-882F-E38914F7DF95</gtr:id><gtr:title>Synthetic heparan sulfate oligosaccharides inhibit endothelial cell functions essential for angiogenesis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0115694f3825ebf31244b421484b7bae"><gtr:id>0115694f3825ebf31244b421484b7bae</gtr:id><gtr:otherNames>Cole CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>BbtS3KK7SGw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4055FBE2-4FE4-4A99-8FB8-20BE6DD8468A</gtr:id><gtr:title>Effect of solvents on obligately anaerobic bacteria.</gtr:title><gtr:parentPublicationTitle>Anaerobe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66da81635d8fe57e55bd454856ec0fcc"><gtr:id>66da81635d8fe57e55bd454856ec0fcc</gtr:id><gtr:otherNames>Rodriguez Martinez MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1075-9964</gtr:issn><gtr:outcomeId>3C68B595189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F19B2DC-4D67-45AC-921E-EAC10D11934A</gtr:id><gtr:title>Tetrasaccharide iteration synthesis of a heparin-like dodecasaccharide and radiolabelling for in vivo tissue distribution studies.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45847ebe50cfcf60d4977b6bc361f884"><gtr:id>45847ebe50cfcf60d4977b6bc361f884</gtr:id><gtr:otherNames>Hansen SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>546cacaba13040.41015894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65311C35-6D12-4FC8-93A8-9892F679C27E</gtr:id><gtr:title>Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>11F51F3DADD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68A6B25C-0730-42D8-90CE-4B0204BBD270</gtr:id><gtr:title>Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b2e8647c366fd9f3b84d7598a63b0c1"><gtr:id>9b2e8647c366fd9f3b84d7598a63b0c1</gtr:id><gtr:otherNames>Duff SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>8809AAF4E8A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D5E948C-AB3C-4CF6-BB21-F9512C3E0AE3</gtr:id><gtr:title>A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis.</gtr:title><gtr:parentPublicationTitle>Expert opinion on therapeutic targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf26ebeb25c2f9e325f2acbba0d2ba1e"><gtr:id>cf26ebeb25c2f9e325f2acbba0d2ba1e</gtr:id><gtr:otherNames>Baka S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1472-8222</gtr:issn><gtr:outcomeId>DADD47C3D43</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E1208E7-4470-4B1F-9144-97658D938C98</gtr:id><gtr:title>SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34e2bcd119699e6ea82200ca5de09767"><gtr:id>34e2bcd119699e6ea82200ca5de09767</gtr:id><gtr:otherNames>Clamp AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>B2EEFFADE4C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55474794-1C15-405C-83BF-A86828B12E06</gtr:id><gtr:title>Synthesis and scalable conversion of L-iduronamides to heparin-related di- and tetrasaccharides.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45847ebe50cfcf60d4977b6bc361f884"><gtr:id>45847ebe50cfcf60d4977b6bc361f884</gtr:id><gtr:otherNames>Hansen SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>pm_540e150e1507cbe04</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B07859C-DE17-4A31-BDC1-4E64EE3D7583</gtr:id><gtr:title>Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b2e8647c366fd9f3b84d7598a63b0c1"><gtr:id>9b2e8647c366fd9f3b84d7598a63b0c1</gtr:id><gtr:otherNames>Duff SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1462-8910</gtr:issn><gtr:outcomeId>AkNs2k4hMry</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF0910F7-E8FB-43BD-B39A-44C7789A7434</gtr:id><gtr:title>Angiogenesis as a therapeutic target in cancer.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01a63743a03e503815c1d4c921c238ae"><gtr:id>01a63743a03e503815c1d4c921c238ae</gtr:id><gtr:otherNames>Kumaran G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>CCB3EF5DCB4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>177DAE81-F888-4CF9-A5C5-72849AABC456</gtr:id><gtr:title>Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor.</gtr:title><gtr:parentPublicationTitle>Journal of cancer research and clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/700de4b18b5fc196a54e790638ed23c8"><gtr:id>700de4b18b5fc196a54e790638ed23c8</gtr:id><gtr:otherNames>Whitworth MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0171-5216</gtr:issn><gtr:outcomeId>577EE70BF67</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33C5412D-C330-4587-A797-ACE0150D990B</gtr:id><gtr:title>DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>69813D57A64</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FE46376-66C4-470F-A290-E92DBBF45255</gtr:id><gtr:title>The best guess approach to phase I trial design.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08a5dbaad5acf73619f1083930308d3c"><gtr:id>08a5dbaad5acf73619f1083930308d3c</gtr:id><gtr:otherNames>Rosa DD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>51017645BBD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC1DE287-704A-468D-A3BA-BB6E31F92F95</gtr:id><gtr:title>Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>53F84F53979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E656515-97FF-4E4F-B12C-73307D707E96</gtr:id><gtr:title>Development of antiangiogenic agents for ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e243ec55c496217aa615acb84169ab4e"><gtr:id>e243ec55c496217aa615acb84169ab4e</gtr:id><gtr:otherNames>Collinson FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn><gtr:outcomeId>5278DAC75A9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8466241-4C57-4D62-9E4A-C42926879E43</gtr:id><gtr:title>Modular synthesis of heparin-related tetra-, hexa- and octasaccharides with differential o-6 protections: programming for regiodefined 6-o-modifications.</gtr:title><gtr:parentPublicationTitle>Molecules (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06885bc03841702a6aa73c47cbfe184b"><gtr:id>06885bc03841702a6aa73c47cbfe184b</gtr:id><gtr:otherNames>Bar?th M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1420-3049</gtr:issn><gtr:outcomeId>5675e21e1bea1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CC6F4EB-43FC-48C0-9610-8D3A9D5B1D29</gtr:id><gtr:title>Synthesis of a heparin-related GlcN-IdoA sulfation-site variable disaccharide library and analysis by Raman and ROA spectroscopy.</gtr:title><gtr:parentPublicationTitle>Carbohydrate research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b108ba399454ec071f629b8aea25ffb"><gtr:id>1b108ba399454ec071f629b8aea25ffb</gtr:id><gtr:otherNames>Miller GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-6215</gtr:issn><gtr:outcomeId>doi_55f98498429d7102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F02074D-1DF7-4649-B9B8-AD925768E464</gtr:id><gtr:title>Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a50f0fae428d05bfdc1f9892f1cc059b"><gtr:id>a50f0fae428d05bfdc1f9892f1cc059b</gtr:id><gtr:otherNames>Mullamitha SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>31C4E9A34D8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84930617-EAF9-4A81-B6E7-FC834A0B68E4</gtr:id><gtr:title>Comparison of normal tissue R1 and R*2 modulation by oxygen and carbogen.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>2BFF574F4C3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF9F211A-0F1A-4CC7-9D85-19A84A0905BF</gtr:id><gtr:title>Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1fe5554178ca2cb19c4c96c065d6389"><gtr:id>f1fe5554178ca2cb19c4c96c065d6389</gtr:id><gtr:otherNames>Ledermann JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>DVkrs9poJWi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A001031-947D-48D6-BA8B-05D1C9F36DA3</gtr:id><gtr:title>A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Cancer chemotherapy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34e2bcd119699e6ea82200ca5de09767"><gtr:id>34e2bcd119699e6ea82200ca5de09767</gtr:id><gtr:otherNames>Clamp AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0344-5704</gtr:issn><gtr:outcomeId>09217A04492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCE55237-44A4-42F8-82D8-858CAE0A7901</gtr:id><gtr:title>New therapeutic agents in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Current opinion in obstetrics &amp; gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c79ea24fa0bf39b3c4ebfb2454e5726"><gtr:id>0c79ea24fa0bf39b3c4ebfb2454e5726</gtr:id><gtr:otherNames>Collinson F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1040-872X</gtr:issn><gtr:outcomeId>D3387CA1046</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D7CB523-262B-4897-952F-7647184ADD53</gtr:id><gtr:title>Amyl nitrite-mediated conversion of aromatic and heteroaromatic primary amides to carboxylic acids</gtr:title><gtr:parentPublicationTitle>Tetrahedron Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81a2a8b8c6d7951368fff0b504cff4f8"><gtr:id>81a2a8b8c6d7951368fff0b504cff4f8</gtr:id><gtr:otherNames>Potter G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5675fac19f440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A4F2DC0-7371-448F-9C45-295F1817B0B0</gtr:id><gtr:title>Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5261e64d77ae945d18be26d2f9a33824"><gtr:id>5261e64d77ae945d18be26d2f9a33824</gtr:id><gtr:otherNames>O'Connor JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>E15E0BFB965</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4347402E-2D45-42C5-ABC2-691A53C0A07E</gtr:id><gtr:title>Antiangiogenic drugs in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e83c483da3978143ef19cbaff23ff7bd"><gtr:id>e83c483da3978143ef19cbaff23ff7bd</gtr:id><gtr:otherNames>Kumaran GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>8C9FF4F7EAF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>157E7962-2180-44B5-B334-7483F1DD271C</gtr:id><gtr:title>Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c549528b946fdc1b1f5a4974fc4b326e"><gtr:id>c549528b946fdc1b1f5a4974fc4b326e</gtr:id><gtr:otherNames>Mitchell CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>e6FsSiHhm5X</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1EC0E70-FD80-43AA-87F1-7A8F7E6F2C70</gtr:id><gtr:title>Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cde5a728a30fccb64991e2d25d7a59d"><gtr:id>4cde5a728a30fccb64991e2d25d7a59d</gtr:id><gtr:otherNames>Jackson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>9BBEFD1DD4C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EBAAE2F-700C-444B-BE5A-6155FE8099DF</gtr:id><gtr:title>'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29742572dddbfb84be9bfe9730061975"><gtr:id>29742572dddbfb84be9bfe9730061975</gtr:id><gtr:otherNames>Backen AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>6A3D1B78B5F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B3D0021-1C6E-4838-89CA-62B062630CE7</gtr:id><gtr:title>Heparan sulphate synthetic and editing enzymes in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29742572dddbfb84be9bfe9730061975"><gtr:id>29742572dddbfb84be9bfe9730061975</gtr:id><gtr:otherNames>Backen AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>19817391674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83887159-62CF-42A3-A695-548214CE2F86</gtr:id><gtr:title>How participants in cancer trials are chosen: ethics and conflicting interests.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d75cc06ef727d51e77a523ce8de125d"><gtr:id>0d75cc06ef727d51e77a523ce8de125d</gtr:id><gtr:otherNames>Jayson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>79BD2429496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46629E83-89D5-4D2D-B0B2-403F57CC2E30</gtr:id><gtr:title>Quantifying heterogeneity in dynamic contrast-enhanced MRI parameter maps.</gtr:title><gtr:parentPublicationTitle>Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3412b195ba77b58c45168856a1af9a95"><gtr:id>3412b195ba77b58c45168856a1af9a95</gtr:id><gtr:otherNames>Rose CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>25659D5FB58</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EB5A86C-3731-4CBD-82BC-4F9D65DCD479</gtr:id><gtr:title>Alpha-v integrins as therapeutic targets in oncology.</gtr:title><gtr:parentPublicationTitle>Cancer investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27f8a1a96e4eef83af75328e002d4e7f"><gtr:id>27f8a1a96e4eef83af75328e002d4e7f</gtr:id><gtr:otherNames>Nemeth JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0735-7907</gtr:issn><gtr:outcomeId>1D7EF920F55</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>692C5669-CE61-48BD-8587-1C1DD70B3850</gtr:id><gtr:title>Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8319463b66d4554a643b4e729b8538ec"><gtr:id>8319463b66d4554a643b4e729b8538ec</gtr:id><gtr:otherNames>Cummings J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>268185DF56E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F2A64AA-7210-42A1-A7A1-014C189D4C93</gtr:id><gtr:title>Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma.</gtr:title><gtr:parentPublicationTitle>Cancer science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6a125bf29dfa916384e19e97da74c24"><gtr:id>a6a125bf29dfa916384e19e97da74c24</gtr:id><gtr:otherNames>Ralph S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1347-9032</gtr:issn><gtr:outcomeId>C7B14E163AF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4061DCCC-A27B-42E6-BF56-EE2F1F8425C6</gtr:id><gtr:title>The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d30a74ba41263f9b8bd70b41e0a3b00"><gtr:id>2d30a74ba41263f9b8bd70b41e0a3b00</gtr:id><gtr:otherNames>Clamp A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>415264665A0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4C42861-D6EE-4F9F-8BA1-5DBA984ECA1D</gtr:id><gtr:title>The ethical and scientific case for phase 2C clinical trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95114ba6b9e8321e1dafa232fbe4aa7c"><gtr:id>95114ba6b9e8321e1dafa232fbe4aa7c</gtr:id><gtr:otherNames>Zee YK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>WFnHwbEAwRh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0FDE1D9-F725-4514-B280-E4867BC2060E</gtr:id><gtr:title>Segregation of late outgrowth endothelial cells into functional endothelial CD34- and progenitor-like CD34+ cell populations.</gtr:title><gtr:parentPublicationTitle>Angiogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d57e44aae00d00466b9df35181807756"><gtr:id>d57e44aae00d00466b9df35181807756</gtr:id><gtr:otherNames>Ferreras C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-6970</gtr:issn><gtr:outcomeId>54612a8abc2f60.21179832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78DC8B7E-4DA6-4515-88E5-7E9E9A06906C</gtr:id><gtr:title>Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce8b865cb504a83b250d1f5365034e30"><gtr:id>ce8b865cb504a83b250d1f5365034e30</gtr:id><gtr:otherNames>Brookes K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>Bz9gukKRc1Z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>218604C7-09B2-4649-AFFA-B8232C918298</gtr:id><gtr:title>The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08a5dbaad5acf73619f1083930308d3c"><gtr:id>08a5dbaad5acf73619f1083930308d3c</gtr:id><gtr:otherNames>Rosa DD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5626C4D0B00</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601746</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>